Lars Johansson is PhD in translational imaging from Uppsala University in Sweden. He has over 170 published peer-reviewed papers and several book chapters in imaging in drug development. He has over 30 years experience from clinical imaging in the cardiorenal and metabolic disease areas and more than 20 years experience from the pharma industry.
Lars Johansson is PhD in translational imaging from Uppsala University in Sweden. He has over 170 published peer-reviewed papers and several book chapters in imaging in drug development.
He has over 30 years experience from clinical imaging in the cardiorenal and metabolic disease areas and more than 20 years experience from the pharma industry.
Prior to his current position he had a role as Sr Principal Scientist at AstraZeneca R&D overseeing their clinical trials in cardiorenal and metabolism.
He was one of four founders of Antaros Medical in 2014 and the company have since grown organically to over 100 employees. In his current role as Chief Scientific Officer at Antaros Medical he is involved in designing clinical studies using imaging endpoints including primarily CT, MRI and PET. One of his focus areas are imaging in the NASH disease development ranging from simple steatosis to inflammation, fibroblast activation, fibrosis, cirrhosis and portal hypertension. He has participated in over 30 randomized clinical trials in NAFLD/NASH but also in many other trials in the cardiorenal disease areas. The development of new imaging methods also entail the development of PET tracers targeting incretins such as GLP-1, Glucagon and GIP but also PET tracers targeting activated stellate cells and collagen.
